VSTM
Verastem, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Verastem NASDAQ: VSTM executives outlined the company's commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-gra
